Parallel Trade in Veterinary Medicines: Common Origin, Notification and Article 102

Regulation (EU) 2019/6 gives parallel trade in veterinary medicines a clear legal basis for the first time at EU level. Article 102 sets the conditions, and they are stricter than many distributors expect.

Who and what it covers

Article 102 applies to wholesale distributors who obtain a veterinary medicinal product in one Member State (the source) and distribute it in another (the destination). It does not apply to centrally authorised products.

The common origin test

The product must share a common origin with the one already authorised in the destination Member State. That means the same active substances and excipients, qualitatively and quantitatively, the same pharmaceutical form, the same clinical information and withdrawal period where applicable, and the same manufacturer or a licensed manufacturer using the same formulation. The product must also comply with the destination Member State’s labelling and language requirements.

Notification and obligations

  • A distributor that is not the marketing authorisation holder must notify the holder and the source authority of its intention.
  • It must notify the destination marketing authorisation holder at least one month before applying to the destination authority.
  • It must submit the required declaration to the destination authority and follow the national administrative procedure.
  • It must not trade a recalled product, and must collect and report suspected adverse events.

Transparency

The destination authority publishes a list of parallel-traded products in the Union product database, including the product name, active substances, pharmaceutical forms, classification, marketing authorisation numbers in both Member States and the names and addresses of the distributors in both.

Implications

Originators should monitor the public list and be ready to engage when notified. Parallel traders need robust comparison files, labelling controls and pharmacovigilance arrangements before the one-month notice is sent.

Pharmacovigilance and quality aspects

Parallel traders are not passive intermediaries. They take on obligations to collect and report suspected adverse events, and must withdraw recalled products from the market. In practice this requires a contract and a data exchange route with the marketing authorisation holder or the source supplier, together with a procedure for handling recall notices quickly.

Relabelling and repackaging, where needed to meet destination-market requirements, bring in manufacturing authorisation questions as well. Confirm early who performs those operations, under which authorisation, and how batch traceability is preserved from the source batch to the final pack.

Key takeaways

  • Common origin is a strict, documented test, not an approximation.
  • Centrally authorised products are outside Article 102.
  • Notify the destination marketing authorisation holder at least one month before applying.
  • Adverse event reporting and recall compliance remain with the distributor.
  • The public list in the Union product database makes parallel trade visible to everyone.

How PQRA helps

PQRA supports comparability assessments, notification planning, labelling and language preparation, and pharmacovigilance arrangements for parallel traders, and helps marketing authorisation holders understand their position when a notification arrives.

Contact PQRA to discuss parallel trade strategy for veterinary medicines.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *